Mylan NV (MYL)

17.27
0.04 0.23
NASDAQ : Health Technology
Prev Close 17.23
Open 17.33
Day Low/High 17.16 / 17.43
52 Wk Low/High 16.63 / 35.16
Volume 5.29M
Avg Volume 5.83M
Exchange NASDAQ
Shares Outstanding 516.13M
Market Cap 9.14B
EPS 0.70
P/E Ratio 196.67
Div & Yield N.A. (N.A)
Mylan Is Poised to Break Sideways Trend

Mylan Is Poised to Break Sideways Trend

Things are looking bullish.

Papa and His Brand New Gig (at VRX)

"Papa's in the swing. He ain't too hip about that new breed babe. He ain't no drag. Papa's got a brand new bag." -- James Brown, Papa's Got a Brand New Bag Jim "El Capitan" Cramer clearly outlined the key risks facing Valeant Pharmaceuticals (VRX) t...

Biotech Gets a Lifeline

Biotech Gets a Lifeline

Solid earnings and the start of some M&A activity may be just what this sector needs to rise.

Mylan Is Likely to Grind Lower in the Weeks Ahead

Mylan Is Likely to Grind Lower in the Weeks Ahead

It would take a rally and close back above $46 to alter the current bearish cast to the charts.

Avoid Valeant (Redux)

I noted in my previous missive that my ursine friend Jim Chanos spoke out on CNBC's Fast Money Halftime show today in favor of shorting the Chinese stock market. Well, he also just expressed skepticism on Valeant Pharmaceuticals (VRX) -- another vie...

My Diagnosis of Valeant Pharmaceuticals

"Valeant, of course, was a sewer ... [and its directors deserve] all the opprobrium they are getting." -- Charlie Munger, vice chairman of Berkshire Hathaway (BRK.A, BRK.B), at this weekend's annual Berkshire shareholder meeting Pershing Square's Bi...

Valeant Names Perrigo's Joseph Papa Chairman and CEO; Shares Jump

Valeant Names Perrigo's Joseph Papa Chairman and CEO; Shares Jump

Valeant delighted shareholders Monday with news that Perrigo's Joseph Papa is getting into the driver's seat. 

The Valeant Saga Triggers Buying Opportunities in Biotech Stocks

The Valeant Saga Triggers Buying Opportunities in Biotech Stocks

Other companies have suffered following the debacle.

Valeant Triggers Buying Opportunities

Valeant Triggers Buying Opportunities

Other companies have suffered following the debacle.

Biotech Bloodbath Brings Up Value

Biotech Bloodbath Brings Up Value

I continue to add to my holdings incrementally. 

Silly Season Continues for Biotech

Silly Season Continues for Biotech

Valuations of some small-cap concerns, such as Relypsa, are ridiculously cheap.

10 Stocks Billionaire David Einhorn Loves for 2016

David Einhorn is a man of many talents, including playing poker -- and watching where he stacks his chips investment-wise is a worthwhile endeavor, too.

Generic Drug ETF Offering Portfolio Cure

Generic Drug ETF Offering Portfolio Cure

With biotech stocks getting smashed on the stock market and big pharma getting hammered on the presidential campaign trail, generic drug stocks look awfully appealing.

Market Rout Reveals True Bargains

Market Rout Reveals True Bargains

The market looks like it is expecting a significant domestic contraction in 2016, but I don't see it.

3 Things the Market Needs to Get Off the Mat

3 Things the Market Needs to Get Off the Mat

The year has not started the way most pundits and prognosticators had envisioned.

2 Great Biopharma Plays for a Shaky Market

2 Great Biopharma Plays for a Shaky Market

Mylan and Endo International look like bargains at current prices.

Avoid These Investment Mistakes in 2016

Avoid These Investment Mistakes in 2016

Don't catch falling knives, and don't ignore dividends.

6 Dowdy Drug Stocks to Consider for 2016

6 Dowdy Drug Stocks to Consider for 2016

History indicates pharmaceutical companies with low multiples offer payoffs down the road.

Stocks to Watch for 2016 M&A Deals

Stocks to Watch for 2016 M&A Deals

Look for 2015's record run of mergers and acquisitions to continue.

2 Safe and Cheap Health Care Stocks

2 Safe and Cheap Health Care Stocks

These two will continue to churn out earnings growth.

Weak Chinese Demand Is Already Priced Into Caterpillar's Stock (Plus: MYL, T, DRG, URBN)

CAT not going down on bearish news gets us closer to a bottom and buy recommendation.

Stocks Slightly Lower Amid Yellen's Rate-Hike Hints

Stocks are trading in a relatively narrow range, but are slightly down after Federal Reserve chair Janet Yellen hinted at a possible December rate hike. Still, her remarks are only having a minor impact on the market given the many Fed "head fakes" ...

Valeant and Mylan Fall Amid a Quiet Day for Stocks

There's very little movement on Wall Street right now as the European bourses close. Equities are slightly down across the board, as are gold and oil -- but nothing's moving much today. The volatility we saw in August and September seems to have fad...

Thank God It's Friday!

Good morning! Bret Jensen here. I'm happy to be filling in for Doug Kass during this last trading day of October. It's been a good month for investors after a very bumpy August and September. All the major indices are up nicely for the month, despit...

No Easy Cure for What Ails Biotech Stocks

No Easy Cure for What Ails Biotech Stocks

Make incremental moves until the onslaught in the space is over.

No Easy Cure for What Ails Biotech Stocks

No Easy Cure for What Ails Biotech Stocks

Meanwhile, make incremental moves until the onslaught in the space is over.

6 Biotechs I Like for Earnings Season

6 Biotechs I Like for Earnings Season

These stocks should all show solid third-quarter results.

Mylan Plans Hostile Takeover of Perrigo; Stocks Rebound in Rally

Mylan Plans Hostile Takeover of Perrigo; Stocks Rebound in Rally

Mylan (MYL) gained ground Tuesday after it announced plans to start a $27.1 billion hostile takeover of Perrigo (PRGO).

U.S. Stocks Open Lower as Personal Income and Spending Climb

U.S. Stocks Open Lower as Personal Income and Spending Climb

U.S. stocks opened lower Friday as personal income and spending both rose in July.

Teva Makes Right Choice, Baidu Looks Weak, Yelp Gets Own Review

Teva Makes Right Choice, Baidu Looks Weak, Yelp Gets Own Review

In Tuesday’s Analysts' Actions, Wall Street firms review Teva Pharmaceutical Industries (TEVA), Baidu (BIDU), and Yelp (YELP).